NasdaqGS - Nasdaq Real Time Price USD

Adaptive Biotechnologies Corporation (ADPT)

Compare
7.99
+0.13
+(1.65%)
As of 11:42:31 AM EST. Market Open.
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
177,282.00
170,276.00
185,308.00
154,344.00
98,382.00
Cost of Revenue
73,651.00
75,553.00
57,909.00
49,301.00
22,530.00
Gross Profit
103,631.00
94,723.00
127,399.00
105,043.00
75,852.00
Operating Expense
270,777.00
296,329.00
327,585.00
314,009.00
228,669.00
Operating Income
-167,146.00
-201,606.00
-200,186.00
-208,966.00
-152,817.00
Net Non Operating Interest Income Expense
4,435.00
1,731.00
-182.00
1,668.00
6,590.00
Other Income Expense
--
-25,429.00
--
--
--
Pretax Income
-195,345.00
-225,304.00
-200,368.00
-207,298.00
-146,227.00
Net Income Common Stockholders
-195,241.00
-225,250.00
-200,191.00
-207,279.00
-146,227.00
Diluted NI Available to Com Stockholders
-195,241.00
-225,250.00
-200,191.00
-207,279.00
-146,227.00
Basic EPS
-1.34
-1.56
-1.40
-1.48
-1.11
Diluted EPS
-1.34
-1.56
-1.40
-1.48
-1.11
Basic Average Shares
146,407.76
144,383.29
142,515.92
140,354.92
131,216.47
Diluted Average Shares
146,407.76
144,383.29
142,515.92
140,354.92
131,216.47
Total Operating Income as Reported
-199,780.00
-227,035.00
-200,186.00
-208,966.00
-152,817.00
Total Expenses
344,428.00
371,882.00
385,494.00
363,310.00
251,199.00
Net Income from Continuing & Discontinued Operation
-195,241.00
-225,250.00
-200,191.00
-207,279.00
-146,227.00
Normalized Income
-162,607.00
-199,821.00
-200,191.00
-207,279.00
-146,227.00
Interest Income
16,075.00
15,531.00
4,056.00
1,668.00
6,590.00
Interest Expense
11,640.00
13,800.00
4,238.00
--
--
Net Interest Income
4,435.00
1,731.00
-182.00
1,668.00
6,590.00
EBIT
-183,705.00
-211,504.00
-196,130.00
-207,298.00
-152,817.00
EBITDA
-163,505.00
-189,273.00
-175,210.00
-193,345.00
-144,345.00
Reconciled Cost of Revenue
55,155.00
55,021.00
38,688.00
37,047.00
15,761.00
Reconciled Depreciation
20,200.00
22,231.00
20,920.00
13,953.00
8,472.00
Net Income from Continuing Operation Net Minority Interest
-195,241.00
-225,250.00
-200,191.00
-207,279.00
-146,227.00
Total Unusual Items Excluding Goodwill
-32,634.00
-25,429.00
--
--
--
Total Unusual Items
-32,634.00
-25,429.00
--
--
--
Normalized EBITDA
-130,871.00
-163,844.00
-175,210.00
-193,345.00
-144,345.00
12/31/2020 - 6/27/2019

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

BEAM Beam Therapeutics Inc.
27.45
+0.62%
 
FATE Fate Therapeutics, Inc.
1.3350
-2.56%
 
VERV Verve Therapeutics, Inc.
7.74
+4.39%
 
NTLA Intellia Therapeutics, Inc.
10.51
0.00%
 
CDXS Codexis, Inc.
4.4100
-2.00%
 
VIR Vir Biotechnology, Inc.
10.39
+0.78%
 
EDIT Editas Medicine, Inc.
1.3700
0.00%
 
ABSI Absci Corporation
3.7902
-0.78%
 
CRBU Caribou Biosciences, Inc.
1.4600
+11.45%
 
COGT Cogent Biosciences, Inc.
9.59
-0.31%